Navigation Links
Agent Orange exposure increases veterans' risk of aggressive recurrence of prostate cancer
Date:4/20/2009

AUGUSTA, Ga. - Veterans exposed to Agent Orange are at increased risk of aggressive recurrence of prostate cancer, researchers report.

A study of 1,495 veterans who underwent radical prostatectomy to remove their cancerous prostates showed that the 206 exposed to Agent Orange had nearly a 50 percent increased risk of their cancer recurring despite the fact that their cancer seemed relatively nonaggressive at the time of surgery. And, their cancer came back with a vengeance: the time it took the prostate specific antigen, or PSA, level to double an indicator of aggressiveness was eight months versus more than 18 months in non-exposed veterans.

"There is something about the biology of these cancers that are associated with prior Agent Orange exposure that is causing them to be more aggressive. We need to get the word out," says Dr. Martha Terris, chief of urology at the Charlie Norwood VA Medical Center in Augusta and professor of urology at the Medical College of Georgia School of Medicine.

Dr. Terris, corresponding author on the study published in the May issue of British Journal of Urology International, says she wants her colleagues following prostate cancer patients with Agent Orange exposure to know those patients may need more meticulous scrutiny and so-called salvage therapy quickly if their prostate cancer returns. "Not only are their recurrence rates higher but their cancers are coming back and growing much faster when they do come back," the Georgia Cancer Coalition Distinguished Scholar says.

The PSA of prostate cancer patients is typically measured every three months for two years after surgery then every six months for life. After surgery to remove the diseased prostate, the PSA should be zero, but any prostate cancer cells left behind continue to make PSA, a red flag of recurrence, Dr. Terris says. The PSA often "percolates along" so physicians tend to watch it for a while to determine if additional the
'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. New drug agent knocks out multiple enzymes in cancer pathway
2. Structure of enzyme against chemical warfare agents determined
3. Chemopreventive agents in black raspberries identified
4. MIT nanotubes sniff out cancer agents in living cells
5. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
6. Certain anticancer agents could be harmful to patients with heart disease
7. UF researchers develop improved gene therapy agent
8. New insights into the diversity of Creutzfeldt-Jakob disease agents
9. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
10. Contrast agent trials in swine
11. Agent that triggers immune response in plants is uncovered
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Agent Orange exposure increases veterans' risk of aggressive recurrence of prostate cancer
(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
... The Potato Genome Sequencing Consortium (PGSC), an international ... countries, has released a draft sequence of the potato ... Richard Veilleux, professor of horticulture in the College ... a unique phureja type of potato variety that accelerated ...
... could enhance plants, seed oil content for food and ... Science under an exclusive commercial agreement with Michigan State ... that regulates oil accumulation in plant seed was licensed ... technology transfer office. The gene is a transcription factor ...
... German . , Necessity is the mother ... harsh conditions of snow cover. This remarkable newly-acquired behaviour was ... in Seewiesen and their colleagues in a cave in Hungary. ... it and showed little or no interest in flying into ...
Cached Biology News:Draft potato genome based on unique potato variety 2MSU licenses plant oil enhancement technology to BASF Plant Science 2Great tits eat bats in times of need 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... 4, 2011 Palatin Technologies, Inc. (NYSE Amex: ... Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide ... therapy for the treatment of obesity. AZD2820 is a ... program with Palatin Technologies. Obesity is a ...
... SynCo Bio Partners B.V., one of the leading ... filling facility is again fully operational and SynCo has produced ... after the expansion of its Class A zone.   ... important milestone in SynCo,s strategy in supporting its clients with ...
...   Creabilis SA, a clinical stage ... and pain, announces today that Dr David Roblin has been ... extensive experience in the pharmaceutical industry in a career spanning ... several drugs to the market. He has held leadership roles ...
Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Creabilis Appoints Dr David Roblin as Chief Medical Officer 2Creabilis Appoints Dr David Roblin as Chief Medical Officer 3